Navigation Links
Amarin Regains Compliance With Nasdaq Listing Requirements
Date:2/11/2008

LONDON, February 11 /PRNewswire-FirstCall/ -- Amarin Corporation plc (NASDAQ: AMRND) today announced that it has received notification from The Nasdaq Stock Market that the Company has regained compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market, pursuant to Nasdaq Marketplace Rule 4320(e)(2)(E)(ii). In the notification, Nasdaq advised that the Company has regained compliance with all continued listing requirements and that this matter is now closed.

Thomas Lynch, Chairman and Chief Executive Officer, commented "We are pleased to receive this notification, as continued listing on Nasdaq is an integral part of our plans to build shareholder value, having recently expanded our pipeline and strengthened our management team."

About Amarin

Amarin is committed to improving the lives of patients suffering from central nervous system (CNS) and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.

Amarin's CNS development pipeline includes the recently acquired myasthenia gravis clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation.

Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively. In accordance with customary Nasdaq practice, following Amarin's reverse stock split, which took effect from January 18, 2008, a "D" will be appended to Amarin's Nasdaq ticker symbol for a period of 20 trading days and during that period Amarin's Nasdaq ticker symbol will appear as "AMRND". The ticker symbol will return to "AMRN" on February 19, 2008.


'/>"/>
SOURCE Amarin Corporation Plc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program
2. Amarin Announces Completion of Comprehensive Data Analysis From Phase III Huntingtons Disease Program
3. Sharps Compliance Corp. to Present at the RedChip Small-Cap Investor Conference in Scottsdale, Arizona
4. Adaptis Compliance Officer Earns Advanced Certificate
5. Sharps Compliance Corp. Announces 20% Growth in Customer Billings for Second Quarter of Fiscal Year 2008
6. Mitchell Medical and Jopari Solutions Team up to Offer eBilling Compliance Services to Automobile Property & Casualty Insurance Carriers to Meet New Minnesota Requirements
7. Sharon McCudden Named KePRO Director of Business Process Improvement & Compliance
8. Vendormate Storms into 2008 with Major Milestones for Hospital Vendor Compliance
9. Sharps Compliance Corp. Announces New Senior Vice President of Sales and Marketing
10. CSL Behrings Helixate(R) FS Now Available in 2000 IU Vial Size to Improve Patient Convenience, Encourage Compliance
11. GetWellNetwork Offers Comprehensive Education Package Enabling Hospitals to Meet Compliance Requirements for Patient Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots ... scientists from around the world, announces the launch of its newly redesigned website. ... portal to research breakthroughs and trending news, vital information on upcoming virtual events ...
(Date:1/19/2017)... ... , ... Cosmetic Town, an online plastic surgery community, begins 2017 with an ... for their readers to get the information they desire. The procedures are now listed ... used on those particular areas. , “We are excited to streamline our listings in ...
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... certified dermatologist by the American Board of Dermatology and fellowship trained Mohs and ... the National Institutes of Health, Dr. Li completed his internship in internal medicine ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... doctor who administered fillers that resulted in severe facial disfiguration. After four frightening ... on by doctors at UCLA Medical Center, who removed the substances in a ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... and privacy panel system. , The Tranquility privacy panel system was designed ... office environment. Tranquility panels help reduce noise and provide the visual privacy required ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor ... market is expected to grow at a CAGR of 27.1% ... 38.7% in the second half of the forecast period. The market ... to 2027. The market is estimated at $1,058 million in 2016, ... ...
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
(Date:1/19/2017)... January 19, 2017 New ... to Address Motor Symptoms and Motor Complications in ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) C ... European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
Breaking Medicine Technology: